Coherus BioSciences Reports Officer/Director Changes & Compensation
Ticker: CHRS · Form: 8-K · Filed: Feb 22, 2024 · CIK: 1512762
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Coherus BioSciences just filed an 8-K about changes in its executive team and their pay, which could be a big deal for the stock.**
AI Summary
Coherus BioSciences, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 20, 2024. The filing pertains to Item 5.02, specifically regarding the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The company, based in Redwood City, CA, operates under the CIK 0001512762.
Why It Matters
Changes in executive leadership and compensation structures can signal strategic shifts or financial health, impacting investor confidence and future company direction.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company strategy and performance, posing a medium risk to investors.
Key Players & Entities
- Coherus BioSciences, Inc. (company) — registrant
- February 20, 2024 (date) — date of earliest event reported
- February 22, 2024 (date) — filing date
- Redwood City, CA (company) — principal executive offices location
- 001-36721 (company) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 20, 2024.
What specific items are covered in this 8-K filing?
This 8-K filing covers Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
What is the full name of the registrant company?
The full name of the registrant company is Coherus BioSciences, Inc.
Where are Coherus BioSciences, Inc.'s principal executive offices located?
Coherus BioSciences, Inc.'s principal executive offices are located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
What is the Commission File Number for Coherus BioSciences, Inc.?
The Commission File Number for Coherus BioSciences, Inc. is 001-36721.
Filing Stats: 898 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-02-22 16:59:29
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
- $50,000 — n annual cash retainer in the amount of $50,000. On the date of her appointment to the
Filing Documents
- chrs-20240220x8k.htm (8-K) — 37KB
- 0001558370-24-001542.txt ( ) — 162KB
- chrs-20240220.xsd (EX-101.SCH) — 4KB
- chrs-20240220_def.xml (EX-101.DEF) — 3KB
- chrs-20240220_lab.xml (EX-101.LAB) — 16KB
- chrs-20240220_pre.xml (EX-101.PRE) — 10KB
- chrs-20240220x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 22, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Bryan McMichael Name: Bryan McMichael Title: Executive Vice President, Accounting, Corporate Controller and Interim Chief Financial Officer